|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CSK |
 Gene summary |
| Basic gene Info. | Gene symbol | CSK |
| Gene name | c-src tyrosine kinase | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 15q24.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001127190.1, NM_004383.2, | |
| Description | C-Src kinaseprotein-tyrosine kinase CYLtyrosine-protein kinase CSK | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 124095 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000103653 | ||
| HPRD : 00496 | ||
| Vega : OTTHUMG00000142814 | ||
| Protein | UniProt: P41240 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CSK | |
| BioGPS: 1445 | ||
| Pathway | NCI Pathway Interaction Database: CSK | |
| KEGG: CSK | ||
| REACTOME: CSK | ||
| Pathway Commons: CSK | ||
| Context | iHOP: CSK | |
| ligand binding site mutation search in PubMed: CSK | ||
| UCL Cancer Institute: CSK | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0042997 | negative regulation of Golgi to plasma membrane protein transport | 20605918 |
| Top |
| Ligand binding site mutations for CSK |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R318 | R318C | COAD | 1 | N319 | N319S | COAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CSK |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | N319 | N319S | 0.17516482 | R318 | R318C | -0.76759896 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CSK from PDB |
| Top |
| Differential gene expression and gene-gene network for CSK |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CSK |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0024141 | Lupus Erythematosus, Systemic | 1 | Biomarker, GeneticVariation |
| umls:C0020429 | Hyperalgesia | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CSK |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Experimental | DB02010 | Staurosporine | Small molecule |  |
| Investigational | DB05075 | TG100801 | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CSK go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | STU | STAUROSPORINE | 3d7t | A | R318 | STU | STAUROSPORINE | 1byg | A | R318 N319 |
| Top |
| Conservation information for LBS of CSK |
| Multiple alignments for P41240 in multiple species |
| LBS | AA sequence | # species | Species | A220 | RGNKVAVKCIK | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | A220 | KNRKVALKVSK | 1 | Caenorhabditis elegans | E267 | LYIVTEYMAKG | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | E267 | VYMITEYMANG | 1 | Caenorhabditis elegans | G202 | LLQTIGKGEFG | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | G202 | VGDTIGHGEFG | 1 | Caenorhabditis elegans | G202 | LLQIIGKGEFG | 1 | Gallus gallus | G272 | EYMAKGSLVDY | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | G272 | EYMANGNLIDL | 1 | Caenorhabditis elegans | I201 | KLLQTIGKGEF | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | I201 | DVGDTIGHGEF | 1 | Caenorhabditis elegans | I201 | KLLQIIGKGEF | 1 | Gallus gallus | K203 | LQTIGKGEFGD | 4 | Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus | K203 | GDTIGHGEFGD | 1 | Caenorhabditis elegans | K203 | LQIIGKGEFGD | 1 | Gallus gallus | K222 | NKVAVKCIKND | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | K222 | RKVALKVSKRH | 1 | Caenorhabditis elegans | L321 | AARNVLVSEDN | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | L321 | AARNVLLDDDL | 1 | Caenorhabditis elegans | M269 | IVTEYMAKGSL | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | M269 | MITEYMANGNL | 1 | Caenorhabditis elegans | N319 | DLAARNVLVSE | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | N319 | DLAARNVLLDD | 1 | Caenorhabditis elegans | R318 | RDLAARNVLVS | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | R318 | RDLAARNVLLD | 1 | Caenorhabditis elegans | S273 | YMAKGSLVDYL | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | S273 | YMANGNLIDLL | 1 | Caenorhabditis elegans | T266 | GLYIVTEYMAK | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | T266 | -VYMITEYMAN | 1 | Caenorhabditis elegans | V209 | GEFGDVMLGDY | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | V209 | GEFGDVRLGTY | 1 | Caenorhabditis elegans | Y268 | YIVTEYMAKGS | 5 | Homo sapiens, Gallus gallus, Bos taurus, Mus musculus, Rattus norvegicus | Y268 | YMITEYMANGN | 1 | Caenorhabditis elegans |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |